4
Changes in Ownership
HALOZYME THERAPEUTICS, INC. Filed Acc 0001415889-25-005899
SVP, CHIEF TECHNICAL OFFICER sold 21,697 shares at an average $58.10 ($1,260,681)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER | 2025-02-25 | Sale 10b5-1 | −9,300 | $58.01 | $539,465 | 186,153 | D |
| LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER | 2025-02-25 | Sale 10b5-1 | −700 | $58.67 | $41,069 | 185,453 | D |
| LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER | 2025-02-26 | Sale 10b5-1 | −9,400 | $58.09 | $546,055 | 176,053 | D |
| LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER | 2025-02-26 | Sale 10b5-1 | −600 | $58.65 | $35,189 | 175,453 | D |
| LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER | 2025-02-27 | Sale 10b5-1 | −1,597 | $58.25 | $93,028 | 173,856 | D |
| LaBarre Michael J. SVP, CHIEF TECHNICAL OFFICER | 2025-02-27 | Sale 10b5-1 | −100 | $58.74 | $5,874 | 173,756 | D |
| Open-market sales · 21,697 sh · avg $58.10 · $1,260,681 | |||||||
Loading xslF345X05/form4-02272025_110233.xml…